[Pubmed] Advances in Chimeric Antigen Receptor T Cell Therapy in Neuroimmune Diseases
Posté : 26 mars 2026 11:00
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2026 Feb;48(1):162-169. doi: 10.3881/j.issn.1000-503X.16568.
ABSTRACT
Antibody therapy is a crucial modality for the treatment of neuroimmune diseases.While it can regulate disease activity in the majority of patients,several individuals remain unresponsive to antibody therapy;additionally,the blood-brain barrier restricts the bioavailability and effectiveness of antibodies within the central nervous system.Unlike antibody therapies,emerging chimeric antigen receptor(CAR)-T cell therapies integrate the biological functions of antibodies that target specific molecules with the potent immune capabilities of T cells,resulting in enhanced therapeutic efficacy,improved tissue permeability,and a more pronounced capacity to eliminate target cells.This study encapsulated the advancements in CAR-T cell therapy for neuroimmune illnesses,aiming to furnish novel insights for the enhancement of CAR-T cell therapy to facilitate its practical use.
PMID:41885156 | DOI:10.3881/j.issn.1000-503X.16568
Source: https://pubmed.ncbi.nlm.nih.gov/4188515 ... t6+133c1fe